TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity College, London
About this trial
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
Eligibility criteria
Qualifiers
Written Informed consent
Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.
Agreement to be followed up at a TRACERx EVO site
Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery
Disqualifiers
Any other active or current malignancy and/or systemic treatment (excluding hormone therapy) for that malignancy in the last 12 months (i.e., participant must be cancer free for the last 12 months, and if on therapy it can only be hormone therapy).
Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer, or for Cohort C, cases of NSCLC that have transformed to SCLC, or for Cohort A another synchronous lung cancer.
Psychological condition that would preclude informed consent
Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy
Trial design
Treatments tested in this trial
- Not listed
Trial groups
600 Participants
are grouped into 3 trial groupsSponsors and collaborators
University College, London
Lead sponsor
Cancer Research UK
Collaborator
Source ClinicalTrials.gov